Combining fulvestrant (Faslodex) with continued oestrogen suppression in endocrine-sensitive advanced breast cancer: the SoFEA trial.

Combining fulvestrant (Faslodex) with continued oestrogen suppression in endocrine-sensitive advanced breast cancer: the SoFEA trial.